Enterome
Updated: April 17, 2026
Founder Pierre Belichard
Country: France | Funding: $219.7M (+)
Founded: 2012
Website: https://www.enterome.com
Enterome develops breakthrough immunomodulatory drugs for cancer treatment – OncoMimics peptides – based on the interaction between the gut microbiome and the immune system. The company's candidates target a wide range of tumor types (glioblastoma, adrenal tumors, non-Hodgkin's lymphoma, and colorectal cancer). OncoMimics are a specific combination of bacterial peptides derived from bacteria present in the gut microbiome that precisely mimic either overexpressed tumor-associated antigens or specific markers in solid and liquid tumors, respectively. The company has developed a drug discovery platform that enables the analysis of the world's largest microbiome protein database and the creation of new drugs.
Founded: 2012
Website: https://www.enterome.com
Enterome develops breakthrough immunomodulatory drugs for cancer treatment – OncoMimics peptides – based on the interaction between the gut microbiome and the immune system. The company's candidates target a wide range of tumor types (glioblastoma, adrenal tumors, non-Hodgkin's lymphoma, and colorectal cancer). OncoMimics are a specific combination of bacterial peptides derived from bacteria present in the gut microbiome that precisely mimic either overexpressed tumor-associated antigens or specific markers in solid and liquid tumors, respectively. The company has developed a drug discovery platform that enables the analysis of the world's largest microbiome protein database and the creation of new drugs.
